Clinical Trial Update: Clinical Assessment Of Age-related Macular Degeneration Patients After Early Diagnosis and Treatment With Ranibizumab [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/3 clinical trial evaluating ranibizumab for age-related macular degeneration was terminated with results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Age-related Macular Degeneration

Drugs mentioned

• Ranibizumab (ranibizumab)

Snippet

Sponsor: University of California, San Diego | Conditions: Age-Related Macular Degeneration | Phase 2, Phase 3 | Status: TERMINATED | Results posted: 2019-08-28